Abstract:The calcium-binding protein S100A9 has emerged as a pivotal biomolecular actor in oncology, implicated in numerous malignancies. This comprehensive bioinformatics study transcends traditional boundaries, investigating the prognostic and therapeutic potential of S100A9 across diverse neoplastic entities. Leveraging a wide array of bioinformatics tools and publicly available cancer genomics databases, such as TCGA, we systematically examined the S100A9 gene. Our approach included differential expression analysis, mutational burden assessment, protein interaction networks, and survival analysis. This robust computational framework provided a high-resolution view of S100A9's role in cancer biology. The study meticulously explored S100A9's oncogenic facets, incorporating comprehensive analyses of its relationship with prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration across various tumor types. This study presents a panoramic view of S100A9 expression across a spectrum of human cancers, revealing a heterogeneous expression landscape. Elevated S100A9 expression was detected in malignancies such as BLCA (Bladder Urothelial Carcinoma), CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD (Colon adenocarcinoma), ESCA (Esophageal carcinoma), and GBM (Glioblastoma multiforme), while reduced expression was noted in BRCA (Breast invasive carcinoma), HNSC (Head and Neck squamous cell carcinoma), and KICH (Kidney Chromophobe). This disparate expression pattern suggests that S100A9's role in cancer biology is multifaceted and context-dependent. Prognostically, S100A9 expression correlates variably with patient outcomes across different cancer types. Furthermore, its expression is intricately associated with TMB and MSI in nine cancer types. Detailed examination of six selected tumors—BRCA, CESC, KIRC (Kidney renal clear cell carcinoma), LUSC (Lung squamous cell carcinoma), SKCM (Skin Cutaneous Melanoma); STAD (Stomach adenocarcinoma)—revealed a negative correlation of S100A9 expression with the infiltration of most immune cells, but a positive correlation with neutrophils, M1 macrophages, and activated NK cells, highlighting the complex interplay between S100A9 and the tumor immune environment. This bioinformatics synthesis posits S100A9 as a significant player in cancer progression, offering valuable prognostic insights. The data underscore the utility of S100A9 as a prognostic biomarker and its potential as a therapeutic target. The therapeutic implications are profound, suggesting that modulation of S100A9 activity could significantly impact cancer management strategies.

New progress with calcium-binding protein S100A16 in digestive system disease

Calcium-binding Protein S100P and Cancer: Mechanisms and Clinical Relevance

S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways

The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential

S100A8 and S100A9 in Cancer

Advances in the study of S100A9 in cardiovascular diseases

Downregulation of 425g>a Variant of Calcium-Binding Protein S100A14 Associated with Poor Differentiation and Prognosis in Gastric Cancer.

Unraveling the Mechanisms of S100A8/A9 in Myocardial Injury and Dysfunction

S100A16 Regulated by Snail Promotes the Chemoresistance of Nonmuscle Invasive Bladder Cancer Through the AKT/Bcl-2 Pathway

The functions and regulatory pathways of S100A8/A9 and its receptors in cancers

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase

Calcium-binding Protein S100A14 Induces Differentiation and Suppresses Metastasis in Gastric Cancer.

Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis

Cmar_a_196450 2449..2456

S100A16 stabilizes the ITGA3‐mediated ECM‐receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10

The S100 family is a prognostic biomarker and correlated with immune cell infiltration in pan-cancer

Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer

S100A8-Mediated Inflammatory Signaling Drives Colorectal Cancer Progression via the CXCL5/CXCR2 Axis

An integrated bioinformatics analysis of the S100 in head and neck squamous cell carcinoma

Roles of S100A8, S100A9 and S100A12 in infection, inflammation and immunity

S100a10 deficiency in neutrophils aggravates ulcerative colitis in mice